Loading
Rather than giving the same dose until the cancer grows, measure tumour DNA in blood every few weeks and let a validated algorithm raise, lower, pause or switch drugs to keep the cancer suppressed for longer.
Adaptive therapy trials in prostate cancer (PSA-guided abiraterone cycling at Moffitt) suggest that modulating dose to maintain competition between sensitive and resistant cells can extend control. Circulating tumour DNA now allows frequent, clone-resolved monitoring across cancers. The proposal is a closed-loop system: serial ctDNA and imaging feed an evolutionary model that recommends dose and drug changes under pre-specified rules, with clinician oversight, tested first in oncogene-driven lung cancer and hormone-sensitive prostate cancer.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares FLAURA2, FLAURA, ADAURA, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer.
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Wrong doses, Osimertinib, Acquired resistance to every therapy.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, FLAURA2, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares FLAURA2, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Acquired resistance to every therapy.
Shares AI that is built but not validated or deployed, Drug resistance (primary and acquired), Osimertinib, Acquired resistance to every therapy.